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ABSTRACT  
Problem/Purpose: Antibiotic associated diarrhea (AAD) and clostridium-difficile diarrhea 
(CDAD) are the most common forms of infectious diarrhea in long-term care facilities.  The 
purpose of this study was to determine the effectiveness of probiotics in preventing AAD and 
CDAD in the long term care geriatric population, and to identify interventions that can be 
used to improve clinical practice. 
Background/Significance: Prophylactic use of probiotics have been purported to decrease 
the incidences of AAD and CDAD. Previous studies have yielded contradictory results on the 
efficacy of probiotics. The objective of this study was to evaluate the impact of administration 
of probiotics on the rate of infectious diarrhea in the Long Term Care (LTC) population  
Method: This was a retrospective cohort study. The charts of residents of a LTC facility who 
were 65 years of age and older, and were administered antibiotic therapies, with or without 
co-administration of probiotics were reviewed. A data collection instrument was created for 
this study and piloted prior to its utilization. A chi-square test of independence was calculated 
to obtain the results. 
Results: Forty-four residents received probiotics with antibiotics, five cases of diarrhea were 
reported; no cases of CDAD were reported. In 39 residents who received antibiotics without 
probiotics, two cases of diarrhea and one case of CDAD were reported. 
Conclusion: The study showed no statistically significant evidence to support the 
effectiveness of probiotic use in the prevention of AAD and CDAD in a long term care 
facility.  The incidence of AAD was higher in the group with probiotics 
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CHAPTER ONE  
Probiotics are living organisms, which when ingested have the beneficial therapeutic 
effect of reestablishing normal intestinal flora. Each probiotic has its own unique characteristic 
and effects. Probiotics belong to several species such as lactobacillus, bifidobacterum, 
streptococcus, and yeasts and molds. The probiotics Saccharomyces boulardii, lactobacillus 
rhamnosus GG, Lactobacillus plus acidophilus, Lactobacillus bulgaricus, lactobacillus casi and 
bifidobacterum bifidium are some of the most frequently used probiotics (Bergogne-Berezin, 
2000). Several studies have been conducted over the past 20 years on their effectiveness in the 
prevention of antibiotic-associated diarrhea (AAD) and clostridium-difficile diarrhea (CDAD) 
with varied results about their effectiveness.  
The prevention of AAD and CDAD, or extent of these infections, might assist in the 
reduction of morbidity and mortality in the vulnerable geriatric population of long term care 
(LTC) facilities. This population is at greater risk of acquiring these infections because of 
frequent administration of antibiotics. Other risk factors include comorbid conditions, frailty, 
cross infection, age, or congregate living (Schroeder, 2005). CDAD is the most common 
infectious cause of diarrhea in LTC residents (Laffan, Greenough, & Zenilman, 2006) 
Probiotics are used despite a lack of definitive evidence of their effectiveness in the 
prevention of AAD and CDAD in the LTC population. Studies conducted on adult subjects 
found that probiotics were effective in the prevention of AAD (Can, BeÅŸirbellioglu, Avci, 
Beker, & Pahsa 2006; Gotz, Romankiewicz, Moss, & Murray, 1979; McFarland et al., 1995; 
Surawicz et al., 1989). However, two studies found there was no significant benefit of probiotics 
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in the prevention of AAD and CDAD (Lewis, Potts, & Barry, 1998; Thomas et al., 2001) . Five 
meta-analyses on the use of probiotics for the prevention of ADD have been published. These 
contained studies that included children. McFarland’s (2006) landmark meta-analysis of 25 
randomized controlled trials found that a variety of different types of probiotics have some 
therapeutic effect on AAD and CDAD. However, the analysis showed that only three types of 
probiotics significantly reduced the development of AAD, and only one was effective for 
CDAD. However, none of these study reports provided sufficient data on dosing and duration of 
therapy. 
Problem/Significance 
The widespread use of antibiotics promotes occurrences of diarrheal infections. 
Antibiotics disrupt the intestinal microflora which is a protective barrier against the colonization 
of intestinal pathogens (Marteau, Vrese, Cellier, & Schrezenmeir, 2001).  With the interruption 
of this protective barrier, patients become susceptible to opportunistic infections such as AAD 
and CDAD (Bergogne-Berezin, 2000; Surawicz, 2003).   
AAD can occur during or shortly after antibiotic administration. Even a single dose of 
antibiotic can produce an episode of AAD (Katz, 2006). Diagnosis of AAD is made in the 
absence of other known causes of diarrhea.  Frequency of AAD varies with the type of antibiotic 
used and can occur within a day of starting antibiotics or up to six weeks after completion of 
antibiotics (Katz, 2006). AAD occurs in 25% of adults receiving antibiotics with rates as high as 
26-60% in hospital outbreaks (Katz, 2006; McFarland, 2006).  
The World Health Organization defines diarrhea as watery or unformed stools, 
occurring more than 3 times a day for at least 2 days. AAD occurs within two months of 
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antibiotic therapy. Risk factors associated with AAD include the use of broad spectrum 
antibiotics, such as amoxicillin, second and third-generation cephalosporin, and clindamycin. 
Other risk factors include long courses of antibiotic therapy, or repeated courses of antibiotic 
therapy, and extremes of age, less than 6 and greater than 65 years (Bergogne-Berezin, 2000). 
Additionally, predisposing factors such as history of AAD, serious concomitant disease, 
chronic digestive diseases, co-morbidity, and immunodeficiency can precipitate AAD. 
Prolonged hospitals stay, surgery, gastrointestinal procedures, nasogastric alimentation and 
residing in a nursing home, are all risk factors associated with AAD (Bouhnik, 2006).  
CDAD is diagnosed by a positive stool culture for toxin (A or B), stool cytotoxicity 
assay positive for Toxin B, or endoscopy for colonic pseudomembranes. CDAD the most 
severe form of AAD, accounts for 15% to 25% of AAD and can be very difficult to treat 
(Doron, Hibberd, & Gorbach, 2008).  
The prevalence of clostridium difficile can range from 2.1% to 8% in LTC facilities 
during a one year period (Simor, Yake & Tsimidis, 1993).  C-difficile is present in 2-3% of 
typically healthy adults and in as many as 70% of normally healthy infants, and is the most 
common infectious cause of acute diarrhea in nursing homes (Simor, Yake & Tsimidis, 1993). 
Eighty percent of CDAD onset occurs during antibiotic therapy and 8% to 33% of long term care 
residents treated with antibiotic therapy acquires infection with CDAD (Simor 2002). Laffan, 
Greenough, and Zenilman (2006) in their study found that the incidence of CDAD ranged from 0 
to 2.62 cases per 1,000 resident days, with a recurrent rate of 21.7% of patients. Current 
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treatment for AAD and CDAD is with the administration of specific antibiotics, metronidazole 
and vancomycin. 
Probiotics are living organisms (yeast or bacteria) which, when administered in 
adequate amounts, have a potentially beneficial therapeutic effect.  Some of these are the 
prevention of antibiotic-associated diarrhea, decreasing the frequency of recurrent 
Clostridium-difficile infection, and preventative and curative activity against acute infectious 
diarrhea (McFarland, 1998; Bouhnik, 2006). Several studies found that prophylactic 
probiotics are not widely used, although they have been extensively studied (Kopp-Hoolihan, 
2001; Sazawal, 2006). There are over 800 publications on probiotics completed to date 
(Piche, & Rampal, 2006). However, these research studies conducted on the efficacy of 
probiotics provide contradictory results. This may be due to the study designs, type of 
probiotic, differing dosage and length of treatment.  
 There are currently no studies on the effectiveness of prophylactic probiotic 
administration, specifically in the LTC geriatric population. Therefore, it is the intent of this 
study to obtain information which can direct clinical practice for the use of probiotics as 
prophylactic therapy for AAD and CDAD in LTC geriatric population. Overall clinical 
practice may be enhanced through the development of evidence to support the use of 
probiotics in the LTC geriatric population.  
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Objectives 
The objective of this study is to evaluate the effectiveness of probiotics when 
administered with antibiotics for the treatment of a variety of infectious diseases with the goal of 
preventing of AAD and CDAD. The assumption is that probiotics are effective in the prevention 
of AAD and CDAD (Surawicz et al. 1989; McFarland et al., 1995; Bergogne-Berezin, 2000; 
Bouhnik, 2006; Can et al. 2006). The incidences and prevalence of AAD and CDAD in the LTC 
setting presents a challenge to the health care system as CDAD is the most commonly identified 
cause of diarrhea in LTC.  Furthermore, as the population ages, concern of infections and 
diseases are expected to rise in the LTC population (Laffan et al., 2006). Additionally, there is 
sufficient evidence through randomized control trials (RCT) to suggest effectiveness of 
probiotics in prevention of these infections. (Gotz et al., 1979; Surawicz et al., 1989; McFarland 
et al., 1995; Can et al., 2006). 
The design is a retrospective cohort study of a geriatric population in the LTC setting. The 
overall aim is to direct clinical practice in the management of AAD and CDAD infections in 
this patient population.  The geriatric population of LTC facilities includes individuals with 
many comorbid conditions, depressed immune systems. Polypharmacy and frequent use of 
antibiotics place them at a higher risk of acquiring diarrheal infections. 
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The research questions to be addressed are: 
1.  Are probiotics effective in preventing AAD and CDAD in the LTC population? 
2. Which probiotic dosing is effective in preventing AAD and CDAD? 
3. What is the most effective duration of probiotic administered in preventing AAD and 
CDAD? 
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CHAPTER TWO 
 This chapter presents a review of past and current literature on the efficacy of probiotics 
in the prevention of AAD and CDAD. Studies included randomized control trials (RCT), meta-
analysis and systematic reviews. Eleven studies met the inclusion criteria and are explored in this 
chapter. 
Antibiotic-associated diarrhea (AAD) is a common problem found in up to 25% of 
patients, following the use of antibiotics. Up to 25% of these cases progress to clostridium-
difficile diarrhea (CDAD) (Katz, 2006). The mechanisms underlying AAD include the 
proliferation of pathogenic microbes and reduction of fermentative activity on the part of the 
microflora (Rambaud, Buts, Corthier & Flourié 2006). The frequent use of antibiotics in the 
geriatric population in the long term care (LTC) setting puts them at risk for acquiring these 
infections because of age, multiple co-morbidities and immunocompromised state.  
Probiotics are purported to be suitable for use in the prevention of these infections 
(McFarland 2006) although, several studies have been conducted on the therapeutic benefit of 
probiotics without conclusive results (Dunkduri 2005).  Currently, use of probiotics is at the 
discretion of the prescriber as there are no current guidelines for its use.  
Review of Literature 
A review of literature was conducted to determine whether the administration of 
probiotics along with antibiotic therapy would decrease the incidences of ADD and CDAD in the 
geriatric population based on studies conducted to this date. The search terms used were 
probiotics, diarrhea, antibiotic clostridium-difficile, evidence based practice, 65+ years, practice 
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protocol, clinical trials, humans, and English language. Databases searched included CINAHL, 
MEDLINE, PubMed, Cochrane Systemic Review, and Cochrane Central Register of Controlled 
Trials. Trials in which probiotics were given for prevention of AAD and CDA were utilized as 
the major inclusion criterion for the study. Exclusion criteria for studies were use of probiotics 
for treatment of AAD and CDAD, children only studies, and reviews. The articles which met 
inclusion criteria included six original studies, four meta-analysis and one systemic review which 
provided data on over 5,000 treated patients.  
  The literature search yielded 302 studies. After limiting the search to studies in which 
probiotic were used for prophylaxis of AAD, CDAD, and which were randomized control trials 
(RCT), 51 studies were identified and screened for further inclusion. Eleven studies were 
selected based on predefined inclusion criteria of studies in which probiotic were used for 
prophylaxis of AAD and CDAD, and were randomized control trials (RCT). (see Figure1for 
flow diagram of included and excluded studies). 
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Figure 1 Flow diagram of included and excluded studies. 
 Note: AAD indicate antibiotic associated diarrhea. CDAD indicate clostridium-difficile diarrhea. 
 
Gotz and colleagues (1979) conducted a randomized controlled placebo trial of 98 
hospitalized patients’ with ages ranging from 18 to 88 who were treated with Ampicillin and 
were also administered Lactobacillus acidophilus and Lactobacillus bulgaricus to determine the 
efficacy of these probiotics in the prevention of AAD and CDAD. The patients were treated with 
one packet of either Lactobacillus acidophilus, Lactobacillus bulgaricus or placebo four times a 
day for the first five days of ampicillin therapy. Data from 79 patients were collected and 
reviewed, the results showed that the patients in the ampicillin and placebo group had ampicillin-
315 studies identified by electronic 
database search 
51 studies identified and 
screened for inclusion 
Clostridium-difficile 
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Antibiotic associated diarrhea 
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criteria. 
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1 CDAD systematic review 
1 AAD and CDAD meta-analysis 
3 AAD meta-analysis 
6 AAD original studies 
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induced diarrhea at a rate of 14% (p=0.03) and those in the ampicillin and probiotics group 
experienced no diarrhea. This result suggests that prophylactic use of probiotics appears to be 
effective in the prevention of AAD.  
 Surawicz et al. (1989) conducted a randomized controlled placebo trial of 180 
hospitalized patients receiving the antibiotics clindamycin, cephalosporins, or trimthoprim- 
sulfamethazole.  Subjects were randomized to receive either a placebo or Saccharomyces 
boulardii. The study was conducted over a period of 23 months during which time the duration 
of antibiotic therapy administration varied. The results showed that 22% of patients receiving 
antibiotic and placebo acquired AAD compared to 9.5% of those receiving antibiotic and 
probiotic (p=0.038). This result suggests that prophylactic probiotics appear to be effective in the 
prevention of AAD.  
Another study which showed efficacy of probiotics in the prevention of AAD and CDAD 
was conducted by McFarland et al. (1995). In this randomized controlled placebo trial 193 
patients were treated with the B-lactam, tetracycline, and the probiotic Saccharomyces boulardii 
(1g/day) within 72 hours of the start of antibiotic through to 3 days after completion of the 
antibiotic therapy. The patients were followed up for seven weeks after antibiotic therapy. 
Fourteen point six percent (14/96) of patients receiving antibiotic and placebo developed AAD 
(p=0.02). Whereas 7.2% (7/97) of patients receiving antibiotic and probiotics developed AAD, 
with the efficacy of Saccharomyces boulardii in the prevention of AAD being 51%. Suggesting 
that Saccharomyces boulardii a probiotic has demonstrated effectiveness in preventing AAD.  
Can et al. (2006) recently conducted a randomized controlled placebo trial of 151 
hospitalized patients receiving antibiotics. Subjects were randomized to receive either the 
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probiotic Saccharomyces boulardii or a placebo with the antibiotic therapy. The results of this 
study showed that 9% (7/78) patients in the antibiotic and placebo group developed AAD and 
1.4% (1/73) patients in the antibiotic and probiotics group developed AAD (p=<0.05). On further 
evaluation two of seven stool samples collected from the placebo group with AAD tested 
positive for CDAD, however, no stool from the probiotic group tested positive for CDAD, which 
provides evidence that probiotics is effective in preventing AAD and CDAD when compared 
with placebo. 
Studies conducted by both Lewis et al., 1998 and Thomas et al., 2001 found no 
significant efficacy in the administration of probiotics for the prevention of AAD. Lewis, et 
al.(1998) conducted a randomized controlled placebo trial of 69 hospitalized patients who were 
prescribed antibiotics and were randomized to receive the probiotic Saccharomyces boulardii 
(113 mg) twice a day or placebo during the course of the antibiotic therapy.  Their results 
showed 17% (5/33) of patients receiving antibiotic and placebo developed CDAD and 21% 
(3/36) in the antibiotic and probiotic group developed CDAD. The conclusion of the study was 
that efficacy was not shown in favor of probiotics in preventing AAD and CDAD when 
compared with placebo. 
 Thomas et al. (2001) conducted a randomized controlled placebo trial of 267 hospitalized 
patients who were administered either Lactobacillus GG (20x109 CFU) one capsule two times a 
day and a placebo one two times a day over a 14 day period and monitored for seven days after 
completion of the treatment. The results showed that 29.3% (39/133) patients receiving antibiotic 
and the probiotic Lactobacillus GG had diarrhea, whereas, 29.9% (40/134) participants receiving 
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placebo developed diarrhea. The conclusion of the study was that efficacy was not shown in 
favor of probiotics in preventing AAD when compared with placebo.   
Three meta-analyses and one systematic review were examined to evaluate the effects of 
probiotics in the prevention of diarrhea associated when used in combination with antibiotic. 
D’Souza, Rajkumar, Cooke, & Bulpitt (2002) conducted a meta-analysis of nine randomized 
placebo-controlled trials covering over 1,300 subjects. The results supported the conclusion that 
probiotics can be used in the prevention of AAD, that Saccharomyces boulardii and lactobacilli 
have the potential to be used for this infection.  
Cremonini, et al. (2002) conducted a meta-analysis of seven randomized placebo-
controlled trials covering over 800 subjects. The results supported the conclusion that probiotics 
were more effective than placebo in the prevention of AAD. Suggesting administration of 
probiotic can have benefit on AAD.  However, they concluded that the evidence of beneficial 
effects is not very definitive as published studies are flawed by a lack of placebo design and 
peculiar population features. 
 Sazawal, et al. (2006) in their meta-analysis of 19 masked randomized placebo-
controlled trials involving over 2, 000 subjects found that six of the studies on prophylactic 
probiotic use had statistical significance with an overall reduction of 52% of AAD.  
A systematic review of eight randomized controlled trials conducted by Dendukuri, 
Costa, McGregor & Brophy (2005) was conducted to identify studies in which the prevention or 
treatment of CDAD with probiotic therapy was the primary or secondary outcome. The results 
showed that there was insufficient evidence in studies conducted to date to for routine use of 
probiotics for the prevention of CDAD.   
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The major meta-analysis of probiotics for the prevention of AAD and treatment of 
CDAD was conducted by McFarland (2006). This study examined 31 randomized control trials 
which studied the use of probiotics for the prevention of AAD and treatment of CDAD. Twenty-
five of these studies reviewed were for the prevention of AAD and involved over 2500 subjects. 
The results showed a 44% reduction of AAD in adults, 52% of the studies showed a reduction in 
the incidences of AAD compared to placebo, with higher dosing associated with positive 
efficacy. Moreover, a variety of probiotics Lactobacillus rhamnosus GG, Saccharomyces 
boulardii and probiotic mixtures showed significant efficacy and promise as effective therapies 
for the reduction of AAD. The study also found that Saccharomyces boulardii was an effective 
treatment for CDAD. 
Discussion 
Antibiotic-associated diarrhea and CDAD infections are common; but potentially serious 
health problems Prevention of these infections is justified as they can be costly for this 
population in morbidity and mortality as well as the price of treatment. The restoration or 
maintenance of the gut microflora in the presence of antibiotic use is necessary to prevent the 
occurrences of these infections. The main original studies on the use of probiotics were not 
definitive in the efficacy of probiotics in the prevention of AAD and CDAD. This may be due to 
the study’s design, the length of therapy, duration of therapy, follow up period and dosing of 
probiotic administered. It is of note however, that the majority of studies did provide evidence of 
efficacy. The meta-analysis or systematic review did show that efficacy was evident in the 
majority of studies. These studies included children studies and pilot studies. 
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 Limitations of these studies are that all they were conducted either with hospitalized 
patients or outpatient adults or children (specifically the meta-analysis or systematic reviews), 
not principally elderly residents in LTC facilities. In conclusion, the studies of the benefits 
reported do not adequately include the geriatric population of LTC facilities; therefore, there is a 
need to obtain this information. Consequently, the intent is to conduct future studies to 
investigate the effectiveness of administering probiotics in this specific population for the 
prevention of AAD and CDAD. The results of such a study can contribute knowledge of best 
clinical practice in the care of this population. 
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CHAPTER THREE 
In this chapter, the research design to address the three research questions is discussed. 
The three research questions are: 1.Are probiotics effective in preventing AAD and CDAD in 
the LTC population?  2. Which probiotic dosing is effective in preventing AAD and CDAD?  
3. What is the most effective duration of probiotic administered in preventing AAD and 
CDAD? The setting, participants, sampling, human subjects, data collection tool and 
procedure are also presented. Data analysis, strengths and limitations of the research design 
and plans for future studies are explored. 
Research Design 
This was a retrospective descriptive cohort study of the effectiveness of probiotics 
administration among LTC residents’ ages 65 years and over who were administered antibiotics 
with or without probiotics within the past 12 months.  The intent of this study was to determine if 
the prophylactic use of probiotics was effective in preventing AAD and CDAD. 
Strengths 
The strengths of retrospective cohort studies are that naturally occurring events can be 
studied and the measurement predictor cannot be biased by knowledge of which participants 
have the outcome of interest (Hulley, Cummings, Browner, Grady & Newman 2001). 
Retrospective cohort studies are less expensive and time consuming than RCTs. The resources 
are mainly directed at collection of data only. Additionally, participants have already been 
identified, baseline measurements have been made and the follow-up period has already taken 
place. 
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Limitations 
The main limitation of retrospective cohort studies is the restricted control the researcher 
has over the design of the approach of sampling the population and the nature and quality of the 
predictor variables. The existing data may not include information that is important to answering 
the research questions. Data may be incomplete, inaccurate, or measured in ways that are not 
ideal for answering the research question (Hulley et al. 2001).  
Setting/Participants/Sampling 
The study setting was at a LTC facility in Melbourne Florida which has 160 beds, and 
various occupancy rates. The participants were a convenience sample of geriatric patients, aged 
65 years and older who were residing in the facility for more than six months and were treated 
with antibiotics for a period of one day or more, between January 2009 and December 2009. 
Data was obtained from a chart review. If a participant received probiotics at the same time as an 
antibiotic in any of the commercially available species, lactobacillus, bifidobacterum, 
streptococcus and yeasts and molds, in pill, capsule, granule or suspension form, during the 12 
month period they were included in the treatment group. The participants who received 
antibiotics without probiotics during the 12 month period comprised the control group. The data 
on subjects meeting inclusion criteria was obtained from the participants’ facility medical 
records. Exclusion criteria included age less than 65 years; reside in the facility less than six 
months, i.e. patients who have transitioned from rehabilitation care, and those having a past 
medical history of inflammatory bowel disease, such as Chron’s disease, ulcerative colitis or 
irritable bowel syndrome. 
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Human Subjects 
The researcher received permission from the LTC facility to conduct the study. Because 
of the retrospective record review design of the study no risk to humans was expected. Approval 
to conduct the study was received from the institutional review board (IRB) at the University of 
Central Florida prior to the data collection process. The protected health information (PHI) was 
kept separate from the patients’ chart identification number. 
In order to maintain confidentiality and meet the health insurance portability and 
accountability act (HIPAA) requirements, all protected health information (PHI) was de-
identified. Elements that can be used to identify a specific person, or the person’s relative, 
employer or household members were not collected. Charts were tracked and deidentified by 
assigning random numbers to each chart; these numbers were kept in the facility’s medical 
record file. A data use agreement between researcher and facility was obtained. (Appendix A). 
An approval of exempt human research was obtained from IRB prior to the initiation of the study 
(Appendix B).  
Data Collection Tool 
The data collection tool used to summarize information from the chart review was a 
demographic and clinical profile form which captured information about the participants’ age, 
gender, length of residency in the LTC facility, chronic medical conditions, and antibiotic 
therapy within the period from January 2009 through December 2009. (Appendix C). Probiotic 
data collection consists of type of probiotic received, form of probiotic, number of doses per day 
and duration of therapy. AAD and CDAD data was defined as three or more loose stool within 
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two months after antibiotic therapy, new episode of diarrhea associated with positive culture or 
toxin (A or B), positive culture of any other bacteria or virus. Prior to the study a pilot of the data 
collection instrument was completed. The principal researcher reviewed a sample of five charts 
using the data collection tool. Adjustments were made to the form for easier data recording.    
Procedure 
Data was collected by the principal investigator. The data was be reviewed to assess for 
content validity to determine if the data collected covered a representation of the element to be 
measured or if there was additional information pertinent to the study that needed to be 
examined.  
Data Analysis 
Statistical analysis was performed using SPSS software version 17.0 (Statistical Package 
for the Social Sciences). The chi-square test of independence analysis was used to test for 
statistical significance of the relationship between probiotic use and non probiotic use in the 
prevention of AAD and CDAD. The null hypothesis states that there is no difference in 
prevention of AAD and CDAD with administration of antibiotics with or without probiotics.  
The Cochran’s Q was used to determine if there is a difference in AAD and CDAD rates in 
subjects who were administered probiotics in various doses of 1, 2, 4, or 6 doses per day. The 
null hypothesis states there is no difference in the dose of probiotics administered and the 
prevention of AAD and CDAD. 
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CHAPTER FOUR  
This chapter provides the results of the study. The demographics and clinical profile of 
the participants are provided.  This includes age, gender, chronic conditions, and conditions 
treated with antibiotics. The types of antibiotics and probiotics used in this population within 
the 12 month period are specified. 
Results 
Data was obtained from electronic computer charting in a single LTC facility. Data was 
obtained from the resident’s profile, physician’s orders, nursing notes and eMAR (electronic 
medication administration record). Laboratory test results were obtained from archived paper 
medical records as they were not available from the electronic computer charts. Data was 
analyzed with SPSS 17, analysis included frequencies, crosstabs and Chi-square analysis. One 
hundred and ninety-two charts were identified for review. Seventy charts failed to meet 
inclusion criteria for one or more reasons. Reasons charts were excluded were that residents 
had lived at the facility less than six months (n=54), ages less than 65 (n=15), or the resident 
had a pre-existing condition of irritable bowel syndrome (n=1). Other charts which were 
excluded were of patients who did not receive either antibiotics or probiotics (n=39) therefore, 
83 charts met inclusion criteria.  
Sample 
Ages of the residents in the final sample ranged from 65 to 106 years, with a mean age of 
82 years. There were 56 female (67.5%) and 27 males (32.5%) as illustrated in Table 1. The 
most common chronic diseases found in this sample were dementia, chronic pain, constipation, 
dysphagia and diabetes mellitus (See Table 2 for common chronic conditions). Sixty-nine of the 
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83 subjects had two or more of these chronic conditions. Infections treated with antibiotic 
therapy over the 12 month period were often recurrent. These included urinary tract infection 
(UTI), upper respiratory infection (URI), skin and soft tissue infection (SSTI), pneumonia and a 
variety of other infectious diseases, with urinary tract infection as the most frequently treated 
condition (See Table 3 for common conditions treated with antibiotics). Forty-two of the 83 were 
treated with antibiotics for two or more infections. 
Table 1 Age and Gender Distribution 
Characteristics Number  % 
Age   
   Mean  82 years  
Gender   
    Male 27 32.5 
    Female  56 67.5 
 
Table 2 Common Chronic Conditions  
Chronic conditions n  % 
Diabetes 26 31.3 
Constipation  44 52 
Chronic pain  47 56.6 
Dementia  48 57.8 
Dysphasia  38 45.8 
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Table 3 Common Conditions Treated with Antibiotics 
Conditions n % 
Urinary tract infection 48 57.8 
Pneumonia  11 13.3 
Upper respiratory infection 25 30.1 
Cellulitis  8 9.6 
Skin and Soft tissue infection (SSTI) 17 20.5 
Other conditions 24 28.9 
 
Eighty-three residents were administered antibiotics of various classes during the 12 
month period of January 1, 2009 to December 31, 2009. Forty-four residents (53%) were 
administered probiotic along with antibiotic therapy, whereas 39 (47%) received antibiotics only.  
Antibiotics were prescribed and administered a total of 234 times to the 83 residents. While 36 
individuals received only one course of antibiotic, many received more than that. In some cases 
participants received four or five courses of antibiotics. In one case antibiotic was administered 
18 times to a single resident for various infections over the 12 month period. See Table 4 for 
summary of frequency of antibiotics prescribed and administered for the full study group.  
Various classes of antibiotics were administered. These included quinolones, cephalosporins, 
penicillins, macrolides, sulfonamides, tetracyclines and a combination or other classes within the 
12 month period. This is illustrated in Table 5.  
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Table 4 Frequency of Courses of Antibiotics Prescribed During 12 Month Period of Study 
 Number of Courses 
of Antibiotics 
Prescribed   
Number of Patients who Received  
Indicated Courses of Antibiotic   
1 36 
2 14 
3 11 
4 10 
5 6 
6 1 
7 1 
8 1 
10 1 
14 1 
18 1 
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Table 5 Class of Antibiotics Administered to Patients in the Study  
Classification Name  Number of Times Prescribed 
and Administered 
Route of 
Administration 
 
Cephalosporin 
   1
st
 Generation 
 
  2
nd
 Generation 
 
 
  3
rd
 Generation  
  4
th
 Generation 
Sulfonamides 
 
Tetracycline  
 
Quinolones  
 
Aminoglycoside 
Penicillin 
 
 
 
Macrolide 
 
Other    
   
 
cefalaxin  
cefadroxil  
cefotetan 
cefprozil 
cefuroxime 
ceftriaxone  
cefepime  
trimethoprim-
sulfamethoxazole 
trimethoprim-
sulfamethoxazole DS 
doxycycline  
tetracycline  
levofloxacin  
ciprofloxacin 
gentamycin 
amoxicillin 
ampicillin 
amoxicillin/clavlanate 
pen-V-K  
azythromycin   
erythromycin 
primaxin  
nitrofurantoin  
linezolid 
clindamycin 
      
 
15 
1 
1 
1 
13 
19 
1 
 
11 
 
8 
16 
1 
48 
36 
2 
14 
5 
7 
1 
19 
1 
1 
11 
1 
1 
 
 
PO 
PO 
PO 
PO 
PO 
IM 
IV 
 
PO 
 
PO 
PO 
PO 
PO 
PO 
IM 
PO 
PO 
PO 
PO 
PO 
PO 
IV 
PO 
PO 
PO 
 
 
Note: PO indicates by mouth. IM indicates intramuscular. IV indicated intravenous. 
 
Probiotic was administered with antibiotic 78 times of the 234 courses of antibiotics 
prescribed within the 12 month period. Probiotic was given in various frequencies, forms and 
dosing and duration. Duration did not always match duration of the antibiotics. Seventy-six 
doses were of various forms of acidophilus, and two were of Saccharomyces boulardii. The most 
common forms of probiotics administered were capsules (n=59) and caplets (n=18) Dose of 
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probiotic was not noted on many of the records. Frequency of probiotic administration varied. 
This is illustrated in Table 6. The duration of probiotic therapy varied. The most frequent 
duration of 10 days illustrated in Table 7. The most frequent dosing was one, two times a day 
(See Table 8 for frequency of probiotic dosing).  
Table 6 Types of Probiotic Used 
Type of 
Probiotics  
Number of 
Times Rx   
Form of 
Probiotics  
Doses of 
Probiotics  
Duration of 
Therapy 
Prescribed 
Amount 
 
Acidophilus 
 
 
Acidophilus 
 
Acidophilus  
Acidophilus 
Pectin 
Acidophilus 
Saccharomyces 
boulardii  
 
Acidophilus 
Acidophilus   
 
45 
 
 
18 
 
06 
 
02 
03 
 
02 
 
01 
01 
 
Capsules 
 
 
Caplets 
 
Capsules  
 
Capsule  
Capsule 
  
Capsule 
  
Wafer   
Capsule 
 
Unknown 
 
 
Unknown 
 
16 mg 
 
Unknown 
175 mg 
 
250 mg 
 
Unknown 
1 mg  
 
 
<7 days to 16 
days 
 
 < 7 days to 
14 days 
10 to 14 days 
 
10-14 days 
10-14 days 
 
<7days-10 
days 
10 days 
10 days 
 
1 Daily; 1 
BID; 1 TID; 
2 BID 
1BID to 2 
BID 
1 BID 
 
1 BID 
1 BID 
 
1 BID 
 
1 BID 
1BID 
Note: BID indicates two times a day. TID indicates three times a day. 
 
Table 7 Duration of Probiotic Therapy 
Duration of Probiotic Number of Times Prescribed  
<7 days 5 
7 days 10 
10 days 52 
14 days 10 
21 days 0 
>21 days 
Other (16 days) 
0 
1 
 25 
 
Table 8 Frequency of Probiotic Administered 
Prescribed Amount  Frequency Prescribed  
1  Daily 04 
1 BID 62 
2 BID 08 
1 TID 04 
2 TID 0 
Note: BID indicates two times a day. TID indicates three times a day. 
 
Findings 
 The occurrence rate of diarrhea episodes found in the 83 residents was 8 (9.6%). There 
were five cases of diarrhea in the 44 residents who were administered both antibiotics and 
probiotics (11.4%). None of these records had documentation of positive cultures for 
clostridium-difficile or other organisms. There were two cases of diarrhea in the 39 residents 
who were administered antibiotic without probiotic (5.2%). One subject was positive for 
clostridium-difficile toxin A/B (2.6%), after administration of antibiotic without probiotic. The 
ages of the residents who had diarrhea ranged from 69 to 97 years. Not all the residents who 
had episodes of diarrhea had been administered antibiotic by mouth. Four of the eight residents 
had a diagnosis of dysphagia and one had a percutaneous gastrostomy tube (PEG) with which 
all medications were administered. 
Research Questions 
Question One 
Are probiotics effective in preventing AAD and CDAD in the LTC population? 
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Data was analyzed with SPSS 17. Analysis was completed using the chi-square test to 
compare the relationship of diarrhea rate within two months of antibiotic administration with 
probiotics and without probiotics. Antibiotic with probiotic administration had an 11.4% (n=5) 
occurrence rate for AAD, whereas antibiotic administered without probiotic had a 5.2% (n=2) 
occurrence rate (X²(1) =1.041, p>.308). No statistically significant difference was found 
between the numbers of cases of AAD in those who were administered both antibiotics and 
probiotics and those who were administered antibiotic without a probiotic. Antibiotic with 
probiotic administration had no occurrence of CDAD, whereas antibiotics without probiotics 
administration had 2.6% (n=1) occurrence (X²(1) =1.142, p>.285). No statistically significant 
difference was found between the number of cases of CDAD in those who were administered 
antibiotics and probiotics and those who were administered antibiotic without probiotic (See 
Table 9 for results on the effectiveness of prophylactic probiotic use). Therefore, the null 
hypothesis which states that there is no difference in prevention of AAD and CDAD with 
administration of antibiotics with or without probiotics is supported. 
Question Two  
Which probiotic dosing is effective in preventing AAD and CDAD? 
  Data was analyzed with SPSS 17. Analysis was calculated using Cochran’s Q statistical 
test to answer this question, however, the variables were not dichotomous, and therefore, the 
test could not be performed. Moreover, no effective dosing is found in the study as there were 
only two types of probiotics given, one only twice and the other in various forms and dosing; 
furthermore, no significant effectiveness of probiotics administration with antibiotic was shown 
in preventing AAD and CDAD. 
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Question Three    
What is the most effective duration of probiotic administered in preventing AAD and CDAD? 
 
        Data was analyzed with SPSS 17. Analysis was calculated using Cochran’s Q statistical 
test to answer this question, however, the variables were not dichotomous, and therefore, the 
test could not be performed.  
Table 9 Results on the Effectiveness of Prophylactic Probiotic Use 
Drug Administration n (% AAD) n ( % CDAD)  Conclusion 
Antibiotic with 
Probiotic   
5 (11.4%) 0 No statistically significant evidence found 
to conclude relationship between probiotic 
use and prevention of AAD and CDAD 
Antibiotic without 
Probiotic 
2 (5.2%) 1 (2.6%) No statistically significant evidence found 
to conclude relationship between probiotic 
use and prevention of AAD and CDAD 
P-Value .308 .285  
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CHAPTER FIVE 
This chapter explores and discusses the study’s findings. The chapter includes limitations 
of the study conducted, conclusions and suggestions for further studies to be conducted in the 
population of LTC; also, nursing implications are suggested.  
Discussion 
 The findings of this study do not provide evidence to support a relationship between 
probiotic use in the prevention of AAD and CDAD. The incidence of AAD was higher in the 
group with probiotics by four events. 
The results of this study showed no statistically significant evidence to support the 
effectiveness of probiotic use in the prevention of AAD or CDAD. Previous randomized control 
trial conducted by Gotz et al (1979) found that Lactobacillus acidophilus and Lactobacillus 
bulgaricus were effective in preventing AAD in hospitalized patients who were administered 
ampicillin therapy versus placebo. Also, Surawicz et al. (1989) in a randomized controlled 
placebo study showed efficacy of  Saccharomyces boulardii versus placebo in preventing AAD 
in patients taking various antibiotics. McFarland et al. (1995) in a randomized controlled placebo 
trial and Can et al. (2006) in a randomized controlled placebo study with Saccharomyces 
boulardii versus placebo also showed efficacy of probiotic in the prevention of AAD. However, 
these studies were conducted in hospitalized patients in a controlled environment with a limited 
number of antibiotics and probiotics administered. In this study however, Saccharomyces 
boulardii was prescribed and administered on two separate occasions with no occurrences of 
AAD or CDAD. 
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The results showed that some of the inconstancies found in previous studies were 
observed in this study, such as; there were a variety of antibiotics administered at various 
frequencies with probiotics administered inconsistently with antibiotic administration. For 
example a resident was prescribed antibiotics five separate times during the 12 month period for 
various infections and was prescribed probiotics two of the five times an antibiotic was 
prescribed. Some of the treatment durations of probiotics were the same as the antibiotic duration 
while others were either less than or more than the duration of the antibiotic. This is shown by 
the disproportionate number of antibiotics administered (n=234) when compared to the number 
of probiotics administered (n=78) illustrated in Figure 4. Therefore there was an overlap in the 
treatment group (those who received antibiotic and probiotic) and the control group (those who 
received antibiotic only) which may impact the results. The highest number of times a probiotic 
was prescribed to an individual resident was three; however, antibiotics were prescribed from 
one to 18 times to an individual resident for a variety of infections on different occasions. 
 
Figure 2 Frequencies of Antibiotics and Probiotics Used 
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The comparison of earlier studies with this study is complex, as this study is a 
retrospective review on the outcome of the administration of prophylactic probiotics to geriatric 
patients in a LTC facility. This population has multiple comorbid conditions and frequent use or 
administration of antibiotics. This is evident by findings that the study population received 
antibiotics on 234 different occasions in a 12 month period, with a range of one to 18 courses of 
antibiotic administered per resident. 
 Various classes of antibiotics were administered over the 12 month period. There were 
no controls on the duration, frequency or dosing of probiotic or antibiotic used, as shown by the 
various forms and doses of probiotics and antibiotics. Earlier studies were conducted in 
hospitalized patients of varying ages from 18 to 88 years of age, whereas, the age range of this 
population is 65 to 106 years old, the age difference of the hospitalized patients vary 
significantly from those of this study and does not reflect a crucial representation of the LTC 
population. Consistent with this study’s findings Lewis et al. (1998) and Thomas et al. (2001), in 
their randomized placebo controlled studies also found no significant efficacy of probiotics in the 
prevention of AAD.   
Limitations 
The major limitation of this study is the restricted ability to control the administered 
elements (probiotics and antibiotics) to the participants, as this study was a retrospective chart 
review. Laboratory tests were not available through the electronic medical record, which 
necessitated reviewing the results with archived paper medical records which were not filed by 
category. The data presented may be incomplete or inaccurate and not closely monitored for 
accuracy. For example the reporting or documenting episodes of diarrhea, or missed doses of 
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either antibiotic or probiotic may not have been adequately documented, which can have 
significant importance to the results.  
In making comparison with earlier studies, the form and duration of probiotics, as well as 
the number of times antibiotics were administrated to the participants, ranged from one to 18 
courses of antibiotics per resident over the 12-month period. Whereas, earlier studies were 
conducted in hospital settings, the route of administration and frequency of administration may 
have been more controlled which could produce different results. Some studies reported use of 
oral antibiotics and the use of more than one antibiotic during the study. Other factors to be 
considered are the chronic conditions of the population with 45.8% of the residents having a 
diagnosis of dysphagia; the forms of probiotics were mainly capsule or caplet. This necessitated 
modifications prior to administration which may have altered absorption or bioavailability of 
antibiotics. This can change the outcome on the effectiveness of the drugs. 
Conclusion 
This study showed no benefit of probiotic in preventing diarrhea associated with 
antibiotic or clostridium-difficile. The assumption is that all available data was accurate and 
complete. This study also did not provide answers to the questions:   
1. Which probiotic dosing is effective in preventing AAD and CDAD? 
2. What is the most effective duration of probiotic administered in preventing AAD and 
CDAD?  
This study demonstrated that the answers to the questions are difficult or even impossible to be 
obtained through retrospective studies if there are inconsistencies in the prescribing of doses 
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and duration of therapies. A more tightly controlled prospective study or changes in procedure 
related to the documentation of dosing and the consistency of their use may be able to produce 
answers to these questions. Additionally, even a longer duration of study may provide answers 
to these questions. 
The inconsistencies found in this study in which prophylactic probiotics were prescribed 
suggest a lack of knowledge on the most effective probiotic dose, frequency or duration and, 
possibly, effectiveness of the therapy.  Also, the lack of a consensus on the efficacy of probiotic 
as shown by previous studies’ contradictory results, may also contribute to these 
inconsistencies. There are no current guidelines to direct these practices. There is a lack of 
research reported in literature to guide the clinical practice of prophylactic probiotic 
administration in LTC; therefore there is a need to conduct ongoing studies in this area so that 
healthcare providers can base their treatment decisions on established evidence. Providers in 
LTC must be more proactive in observing effectiveness of therapies administered to their 
patients to ensure that therapeutic effects are achieved, which can be done through outcomes 
research studies and establishment of practice guidelines.  
The use of prophylactic probiotics has been studied for over 20 years, some of the studies 
were presented in this study, however, there still remain questions that are unanswered, with 
regard to LTC population and effectiveness of this therapy. It may be another 20 years before 
an answer to the study’s question is determined, hopefully, this will not occur and more studies 
in the LTC populations will be conducted to obtain sufficient evidence to establish appropriate 
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guidelines. This population is plagued by pill burden and polypharmacy, therefore, safety and 
effectiveness of therapies need to be established prior to routine use. 
The results of this study did not show effectiveness in the prevention of AAD and CDAD 
with the use of prophylactic probiotics co-administered with antibiotics for infectious diseases 
in LTC patients. This study is an initial review conducted retrospectively on the effectiveness 
of probiotics in preventing AAD and CDAD in the geriatric population. Currently no other 
studies were conducted in this area with which to make comparisons. Although, there are 
several randomized placebo controlled trials completed in the hospitalized setting with adult 
patients which have shown efficacy, these RCTs do not provide adequate representation of the 
LTC population.  
Implications for Nursing 
The results of this study may have provided some evidence to guide the practice of the 
administration of prophylactic probiotics in LTC, however, this is an initial study and further 
retrospective and prospective studies are needed to provide sufficient evidence on the 
administration of probiotics for prevention of AAD and CDAD. The lack of well designed 
studies in this population and studies about the efficacy of therapies may be a reason why 
probiotics are prescribes inconsistently. There is a need to demonstrate efficacy of a drug prior to 
use in these and all other patients. Although studies shows that AAD occurs in 25% of adults 
receiving antibiotics and the prevalence of CDAD ranges from 2.1% to 8% in long term care 
facilities during a one year period (Katz, 2006: Simor, Yake & Tsimidis, 1993), other proven 
measures of prevention and control need to be considered.  
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Previous studies found that higher dosing and longer duration of probiotic therapy 
resulted in treatment efficacy. As observed in this study the lack of standardization of probiotics 
preparations may also contribute to ineffectiveness as dosing may be subtherapeutic.  The form 
of probiotics may have been altered for administration as 45.8% of the patients had a diagnosis 
of dysphagia, which may also have contributed to subtherapeutic dosing. Therefore, it is of great 
importance for nurse practitioners and other prescribers to specifically order types, forms, 
dosings, and frequencies of drugs, to consider the abilities of the patient to swallow the drugs.  
Given that this study is limited to one LTC facility and the sample size is a small 
representation of the geriatric population, it would be of great importance to conduct further 
studies which can add to an evidenced based clinical practice. 
The LTC population is at risk for infectious diarrhea based on the widespread use of 
antibiotic therapy as shown in this study. A few previous studies support the use of prophylactic 
probiotic therapy to decrease incidences of infectious diarrhea. However, this study found no 
evidence which supports these findings.  This is an initial study to review the effectiveness of 
probiotics in the LTC geriatric population, it is recommended that further studies are conducted 
in the geriatric population of LTC facilities before recommendation for use of probiotics 
prophylactic for AAD and CDAD is specified.  
 35 
 
APPENDIX A 
LETTER OF APPROVAL FOR STUDY 
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APPENDIX B 
IRB LETTER OF APROVAL FOR STUDY 
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APPENDIX C 
DATA COLLECTION TABLE 
 40 
 
Participant  number ____________________  Date _________________ Age ________________  
        B.  Gender:  □ Male     □ Female 
C. Date of admission ______________________         D.  Unit _______________________ 
E. Chronic medical conditions: 
1.                                                                     8. 
2.                                                                     9. 
3.                                                                     10. 
4.                                                                     11. 
5.                                                                     12. 
6.                                                                     13. 
7.                                                                     14. 
15. Irritable bowel syndrome □ Yes □ No        16.  Colitis □ Yes  □ No    
17. Chron’s Disease □ Yes  □ No 
F. Antibiotic administration:  □ Yes □ No             G.   Class of antibiotic____________________ 
H. Name of Antibiotic _____________________    I.     Duration of Therapy __________________ 
J.    Diagnosis for Antibiotic Therapy: Circle all that apply 
1. Urinary Tract I infection  
2. Pneumonia   
3. Upper Respiratory Infection  
4. Cellulitis/Soft Tissue Infection  
5. Other/list:  
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K. Probiotic Administered □Yes  □ No  
L. List all Probiotic Used 
1.                                                                                       5.   
2.                                                                                       6.  
3.                                                                                       7.   
4.                                                                                       8.  
M. Duration Probiotic                                                             Form  of  probiotic  
< 7  days                                                                                 Pill  
7 days                                                                                    Granule  
10 days                                                                                   Capsule   
14 days                                                                                   Suspension   
21 days                                                                                    
> 21 days   
Other list: ⁭ 
N. Dose of probiotic 
1/day                                                                                        2/day       
4/day                                                                                        6/day       
Other: 
 Diarrhea  > 3 loose stools/day within 2 months of antibiotic therapy: □ Yes   □  No 
 C-diff  new episode of diarrhea associated with positive culture or toxin (A or B):  □ Yes   □ No 
 Positive Culture of other stool: □ Yes   □ No   O. Results _____________________________ 
Comments: 
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APPENDIX D 
REQUEST TO CONDUCT STUDY 
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To: Administrator of West Melbourne Health and Rehab Center 
Subject: Request for permission to conduct research study at your facility 
Proposal Title: Efficacy of probiotics in decreasing the incidences of antibiotic associated 
diarrhea and clostridium difficile.  
Introduction:  
Prophylactic use of probiotics have been purported to decrease the incidences of 
Antibiotic associated diarrhea (AAD) and clostridium-difficile diarrhea (CDAD).  The purpose 
of this review is to evaluate the efficacy of probiotics in preventing AAD and CDAD.  There is 
sufficient data presented from previous studies to support the use of probiotics for prevention of 
AAD and CDAD. 
Nature and Purpose: 
The study will involves chart review of LTC residents specifically to determine the 
effectiveness of probiotics in decreasing or preventing antibiotic associated diarrhea and 
clostridium-difficile associated diarrhea. The information on the effect of probiotics will 
provide information on the current practice patterns for prescribing probiotics to LTC 
residents, the most effective therapeutic dosing regimen, the most successful therapy duration.  
It will provide information which will contribute to implementation of an evidenced based 
clinical practice to support improving the quality of life in the LTC population.  
 
Methodology and Expected Results 
A review of charts of the residents of the facility would be conducted. The number of charts 
to be reviewed would be the number of residents residing in the facility during the period of 
January 2009 through December 2009.  Only chart of residents’ ages sixty five and older, which 
were treated with antibiotic therapy, with or without administration of probiotics would be 
reviewed. Instruments to be employed include LTC facility charts and medical records and a data 
collection form. 
Timeline for study: 
January-April 2010: Collect and compile data 
May-July 2010: Write formal paper on the results of study. 
Thank you for considering my application. I believe that the results of this study will benefit 
both the residents and staff of your facility. 
Marva Edwards-Marshall ARNP ANP-BC 
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Table 10 Synthesis of Literature Review on Efficacy of Probiotics. 
Authors Probiotics Patients Number of 
patients 
Antibiotic  Duration 
of 
treatment  
Findings 
(% 
diarrhea) 
P value  Conclusion 
Gotz et al 
(1979) 
Lactobacillus 
acidophilus 
Lactobacillus 
bulgaricus 
Hospitalized 98 Ampicillin  Variable 8.3% vs., 
21% 
placebo 
P=0.03   Probiotics effective in 
prevention of AAD. 
Surawicz et 
al. (1989) 
 
Saccharomyces 
boulardii 
Hospitalized  180 Clindamycin 
Cephalosporins, 
trimthoprim-
sulfamethazole 
Variable 9.4% vs. 
31% 
placebo 
P=0.07 Probiotics effective in 
prevention of AAD. 
Lewis et al 
(1998) 
Saccharomyces 
boulardii 
Hospitalized 69 Various 14 days 21% vs. 
17% 
placebo 
Not Stated Probiotics show no 
effect in prevention of 
AAD 
McFarland 
et al. (1995) 
Saccharomyces 
boulardii 
Hospitalized 193 B-lactam 
tetracycline 
Variable 7.2 %vs. 
14.6 % 
placebo 
P=0.02 Probiotics effective in 
prevention of AAD. 
Thomas et 
al. (2001) 
Lactobacillus GG Hospitalized  302 Various Variable 29.3% vs. 
29.9% 
placebo 
P=0.93 Probiotics show no 
effect in prevention of 
AAD. 
Can et al 
(2006) 
Saccharomyces 
boulardii 
Hospitalized  151 Various Variable 1.4% vs. 
9% placebo 
P=<0.05 Probiotics effective in 
prevention of AAD. 
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Table 11 Synthesis of Meta-Analysis and Systematic Reviews on Efficacy of Probiotics. 
Authors Pub 
Yr 
Purpose Findings Conclusion 
McFarland 2006   31 RCT studies were used to 
evaluate the prevention of AAD 
and treatment of CDAD. 
 Sample size for AAD studies 
(n=25) with >2,800 subjects. 
 
 Adults with 44% reduction in   
AAD in probiotic group. 
 52% studies showed a 
significant reduction in the 
incidences of AAD   compared 
to placebo group.  
 Probiotics were effective in the 
prevention of AAD.  
D’Souza 
et.al 
2002  Randomized placebo-controlled 
meta-analysis study on the 
prevention of AAD with probiotic 
use. 
 Sample size (n=9) studies, with 
>1300 subjects. 
 Probiotics more effective at 
preventing incidences of AAD 
than placebo.  
 
 In all nine trials, probiotics 
were given in combination 
with antibiotics. Results of this 
study suggest that probiotics 
were effective in preventing 
antibiotic diarrhea. With 
significance of P<.001. 
Sazawal, et. 
al. 
2006  Randomized, placebo-controlled 
trials were used to evaluate the 
effectiveness of probiotics in the 
prevention of AAD 
 Sample size (n=6) using > 2000 
subjects 
 Overall reduction of 52% in 
AAD in the probiotic group. 
 
 
 
 Overall the risk ratios was 
0.65, which is significant and 
suggests that probiotics is 
effective in preventing AAD.  
 Some of the studies the results 
were more significant than 
others, however overall 
efficacy was significant. 
Dendukuri 
et. al. 
2005  4RCT studies were used to evaluate 
the effectiveness of probiotics in 
the prevention of  CDAD 
 Sample size (n=4) involving  
 Insufficient evidence on the 
effectiveness of probiotics in 
preventing CDAD. 
 
 Probiotics were not shown to 
be effective in preventing 
CDAD. 
Cremonini 
et. al. 
2002  Randomized placebo-control 
studies were used to determine the 
efficacy of probiotics in prevention 
of AAD. 
 Sample size (n=7) with > 800 
subjects. 
 52% overall reduction in the 
probiotics group for AAD. 
 The RR of 0.3966 indicates a 
strong benefit of probiotics for 
prevention of AAD. 
 Studies not exclusive to 
geriatrics. 
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